// Real-Time Intelligence Feed

Financial Intelligence.
Real-Time.

SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.

18,989
Stories Indexed
Live
Feed Status
6
Data Sources
AllEarningsFDAM&AInsider TradingRegulatoryOfferingLeadershipRestructuringDividendInstitutional HoldingsBankruptcy
ALL STORIES · 18,989 results Live
FDA Advagen Jun 4 — 0.00

FDA Approves CARBIDOPA AND LEVODOPA — Advagen Pharma Ltd

# FDA Approves Generic Carbidopa and Levodopa from Advagen Pharma Advagen Pharma Ltd has received FDA approval for its generic formulation of carbidopa and levodopa, a standard-of…

FDA IPCA May 29 — 0.00

FDA Approves Unknown Drug — IPCA LABS LTD

# FDA Approves IPCA Laboratories' Generic Drug Application IPCA Laboratories Limited received FDA approval for an abbreviated new drug application (ANDA 209855) on May 29, 2024, e…

FDA Elite May 16 — 0.00

FDA Approves METHOTREXATE SODIUM — Elite Laboratories, Inc.

# FDA Approves Elite Laboratories' Generic Methotrexate Sodium Oral Formulation Elite Laboratories, Inc. has received FDA approval for its generic methotrexate sodium oral formula…

FDA Dr. May 8 — 0.00

FDA Approves VASOPRESSIN — Dr. Reddy's Laboratories, Inc.

Dr. Reddy's Laboratories received FDA approval for its intravenous vasopressin generic, positioning the company to immediately capture market share in the competitive hospital ther…

FDA Neurocrine Apr 30 — 0.00

FDA Approves INGREZZA SPRINKLE — Neurocrine Biosciences, Inc.

# FDA Approves Neurocrine Biosciences' INGREZZA SPRINKLE for Tardive Dyskinesia Treatment Neurocrine Biosciences, Inc. has received FDA approval for INGREZZA SPRINKLE (valbenazine…

FDA Scienture Apr 19 — 0.00

FDA Approves REZENOPY — Scienture LLC

Scienture LLC announced FDA approval for REZENOPY, a generic naloxone hydrochloride nasal spray, marking the company’s entry into the rapid-growth market for essential opioid rever…

FDA La Apr 3 — 0.00

FDA Approves ZEVTERA — La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company secured FDA approval for ZEVTERA (ceftobiprole medocaril sodium), positioning itself in the IV antibiotic market to address resistant bacterial infe…

FDA Akebia Mar 27 — 0.00

FDA Approves VAFSEO — Akebia Therapeutics, Inc.

# FDA Approves Akebia Therapeutics' VAFSEO for Anemia Treatment The FDA has approved Akebia Therapeutics' VAFSEO (vadadustat), an oral hypoxia-inducible factor (HIF) stabilizer, p…

FDA Merck Mar 26 — 0.00

FDA Approves WINREVAIR — Merck Sharp & Dohme LLC

# FDA Approves Merck's WINREVAIR (sotatercept-csrk), Expanding Treatment Options in Pulmonary Hypertension Market Merck Sharp & Dohme LLC's FDA approval of WINREVAIR (sotatercept-…

FDA Advagen Mar 5 — 0.00

FDA Approves OXCARBAZEPINE — Advagen Pharma Ltd.

Advagen Pharma Ltd. announced the March 5 FDA approval of its ANDA207717 for the oral formulation of oxycarbazepine, providing clearance to market the anticonvulsant generic. The c…

FDA BluePoint Mar 5 — 0.00

FDA Approves CAPECITABINE — BluePoint Laboratories

BluePoint Laboratories has received marketing authorization from the FDA for its generic version of CAPECITABINE, positioning the firm to capturemarket share amid expected competit…

FDA Fresenius Mar 5 — 0.00

FDA Approves TYENNE — Fresenius Kabi USA, LLC

Fresenius Kabi USA has announced FDA approval of tocilizumab (Tyenne, BLA761275) for the treatment of moderate to severe active rheumatoid arthritis, signaling the company’s contin…

FDA Padagis Feb 22 — 0.00

FDA Approves LENALIDOMIDE — Padagis US LLC

Padagis US LLC announced the FDA approval of its oral lenalidomide ANDA, positioning the company to compete in the generic oncology market where an influx of supply is expected to …

FDA Kanchan Feb 14 — 0.00

FDA Approves OXCARBAZEPINE — Kanchan Healthcare Inc

Kanchan Healthcare Inc. has achieved FDA approval for its ANDA-217782, launching the generic version of oxcarbazepine oral tablets. The move positions the manufacturer to capture m…

FDA Aurobindo Jan 29 — 0.00

FDA Approves ISOTRETINOIN — Aurobindo Pharma Limited

# FDA Approves Generic Isotretinoin ANDA from Aurobindo Pharma Aurobindo Pharma Limited received FDA approval for its generic isotretinoin oral formulation (ANDA218194) on January…

FDA Aurobindo Jan 24 — 0.00

FDA Approves LACOSAMIDE — Aurobindo Pharma Limited

# FDA Approves Generic Lacosamide from Aurobindo Pharma The U.S. Food and Drug Administration has approved Aurobindo Pharma Limited's generic lacosamide oral formulation, expandin…

FDA Lifestar Jan 8 — 0.00

FDA Approves ATROPINE SULFATE — Lifestar Pharma LLC

The FDA has granted approval to Lifestar Pharma LLC’s ANDA for Atropine Sulfate Ophthalmic Solution, a generic alternative to branded versions used for myopia control. The approval…

FDA Zydus Dec 5 — 0.00

FDA Approves METHYLENE BLUE — Zydus Lifesciences Limited

# FDA Approves Zydus Lifesciences' Intravenous Methylene Blue Formulation Zydus Lifesciences Limited has received FDA approval for its intravenous methylene blue formulation (ANDA…

FDA SpringWorks Nov 27 — 0.00

FDA Approves OGSIVEO — SpringWorks Therapeutics, Inc.

# FDA Approves SpringWorks Therapeutics' OGSIVEO for Dercum Disease Treatment SpringWorks Therapeutics, Inc. received FDA approval for OGSIVEO (nirogacestat), an oral gamma-secret…

FDA Nuvaila Oct 31 — 0.00

FDA Approves WEZLANA — Nuvaila Limited

Nuvaila Limited announced the 2023 FDA approval of WEZLANA, an intravenous ustekekinumab-auub, positioning the manufacturer to leverage significant market demand for chronic inflam…